SeoulPhage isolated from rumen bacteria linked to cancer.
The phage targets Streptococcus bovis, a rumen bacterium whose human form causes bloodstream infections associated with colorectal cancer.
Its broad host range and anti-biofilm activity make it a livestock and anti-Streptococcus therapy candidate.
Sources: Nature
THE DISCOVERY
Bacteriophages — viruses that infect bacteria — were independently discovered by Frederick Twort (1915) and Félix d'Hérelle (1917). D'Hérelle coined the name from the Greek phagein, 'to devour,' after watching the agents clear bacterial cultures within hours.
THE SOVIET ARC
The West embraced penicillin after 1928 and largely abandoned phage research. The Soviet Union, cut off from Western antibiotics during the Cold War, kept developing phage therapy. The Eliava Institute in Tbilisi, Georgia, has produced therapeutic phage cocktails continuously since 1923 — a parallel medical tradition Western medicine is only now revisiting as antibiotic resistance accelerates.
THE RUMEN
A cow's rumen is the largest fermentation vat in nature — 100 to 200 liters in an adult, holding 10 to 50 billion microbes per milliliter. Cattle do not digest grass; their microbes do. The rumen breaks cellulose into volatile fatty acids the animal absorbs as energy.
THE CANCER LINK
Streptococcus bovis bacteremia has been associated with colorectal cancer since a 1977 New England Journal of Medicine paper. A bloodstream infection with this organism is a clinical trigger for colonoscopy — the bacteria themselves do not cause the tumor, but their presence in blood signals one is likely already there.
WHY PHAGE THERAPY IS RETURNING
Antibiotic resistance kills roughly 1.3 million people annually and is projected to surpass cancer by 2050. Phages evolve alongside their bacterial targets — when a strain develops resistance, the phage population mutates in response. This co-evolutionary arms race is the structural advantage antibiotics lack.
THE BIOFILM PROBLEM
Bacteria in biofilms — slime-encased colonies on surfaces — are up to 1,000 times more resistant to antibiotics than free-floating cells. Most chronic infections (catheter, prosthetic, dental, lung) involve biofilms. Phages can penetrate and dissolve biofilm matrices, which is why anti-biofilm activity is the headline property in any new phage isolate.